Oncology · Phase III

Top sponsors

• AstraZeneca 75 programs
• Chinese Academy of 70 programs
• HOFFMANN-LA ROCHE 68 programs
• MSD Merck Sharp 56 programs
• First People's Hospital 53 programs
• Ningbo Cancer Hospital 44 programs
• United Therapeutics Europe 43 programs
• Anaxis Pharma 37 programs
• AstraZeneca 37 programs
• Novartis India 32 programs
• George Institute for 29 programs
• Takeda 28 programs

1. MIE

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Esophageal Carcinoma

   phase 3 · other · active

   1 trial →

2. MITO 33

   Fondazione Telethon ETS

   Recurrent ovarian, fallopian tube or primary peritoneal cancer

   phase 3 · small molecule · active

   1 trial →

3. MK-1022-016

   Merck Sharp and Dohme

   Hormone receptor positive breast cancer

   phase 3 · small molecule · active

   1 trial →

4. MK-1026-011

   Merck Sharp and Dohme

   Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

   phase 3 · small molecule · active

   1 trial →

5. MK-1026-011

   Merck Sharp and Dohme

   Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

   phase 3 · small molecule · active

   1 trial →

6. MK-1084-004

   Merck Sharp and Dohme

   Non-small cell lung cancer

   phase 3 · small molecule · active

   1 trial →

7. MK-1084-012

   Merck Sharp and Dohme

   KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

   phase 3 · small molecule · active

   1 trial →

8. MK-2140-010

   Merck Sharp and Dohme

   Diffuse Large B-Cell Lymphoma (DLBCL)

   phase 3 · small molecule · active

   1 trial →

9. MK-2400-001

   Merck Sharp and Dohme

   Metastatic Castration-Resistant Prostate Cancer

   phase 3 · small molecule · active

   1 trial →

10. MK-2870-005

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 · small molecule · active

    1 trial →

11. MK-2870-007

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 · small molecule · active

    1 trial →

12. MK-2870-009

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 · small molecule · active

    1 trial →

13. MK-2870-010

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 · small molecule · active

    1 trial →

14. MK-2870-011

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 · small molecule · active

    1 trial →

15. MK-2870-012

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 · small molecule · active

    1 trial →

16. MK-2870-015

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 · small molecule · active

    1 trial →

17. MK-2870-020

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 · small molecule · active

    1 trial →

18. MK-2870-021

    Merck Sharp and Dohme

    Ovarian cancer

    phase 3 · small molecule · active

    1 trial →

19. MK-2870-022

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 · small molecule · active

    1 trial →

20. MK-2870-023

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 · small molecule · active

    1 trial →

21. MK-2870-031

    Merck Sharp and Dohme

    Locally advanced/metastatic urothelial carcinoma

    phase 3 · small molecule · active

    1 trial →

22. MK-2870-032

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 · small molecule · active

    1 trial →

23. MK-2870-033

    Merck Sharp and Dohme

    pMMR endometrial carcinoma

    phase 3 · small molecule · active

    1 trial →

24. MK-2870-036

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 · small molecule · active

    1 trial →

25. MK-3475-426

    Merck Sharp and Dohme

    Metastatic renal cell carcinoma

    phase 3 · small molecule · active

    1 trial →

26. MK-3475-585

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 · small molecule · active

    1 trial →

27. MK-3475-669

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 · small molecule · active

    1 trial →

28. MK-3475-679

    Incyte

    Locally advanced/metastatic renal cell carcinoma

    phase 3 · small molecule · active

    1 trial →

29. MK-3475-811

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 · small molecule · active

    1 trial →

30. MK-3475-866

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 · small molecule · active

    1 trial →

31. MK-3475-905

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 · small molecule · active

    1 trial →

32. MK-3475-966

    Merck Sharp and Dohme

    Biliary Tract Carcinoma

    phase 3 · small molecule · active

    1 trial →

33. MK-3475-991

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 · small molecule · active

    1 trial →

34. MK-3475-A18

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 · small molecule · active

    1 trial →

35. MK-3475-A86

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 · small molecule · active

    1 trial →

36. MK-3475-C93

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 · small molecule · active

    1 trial →

37. MK-3475A-F84

    Merck Sharp and Dohme

    Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%

    phase 3 · small molecule · active

    1 trial →

38. MK-3543-017

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 · small molecule · active

    1 trial →

39. MK-4280A-007

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 · small molecule · active

    1 trial →

40. MK-5684-003

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 · small molecule · active

    1 trial →

41. MK-5684-004

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 · small molecule · active

    1 trial →

42. MK-5684-015

    Merck Sharp and Dohme

    Breast cancer, Ovarian cancer, Endometrial cancer

    phase 3 · small molecule · active

    1 trial →

43. MK-6482-033

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 · small molecule · active

    1 trial →

44. MK-6482-034

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 · small molecule · active

    1 trial →

45. MK-6482-043

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations

    phase 3 · small molecule · active

    1 trial →

46. MK-7339-006

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 · small molecule · active

    1 trial →

47. MK-7339-008

    Merck Sharp and Dohme

    Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 · small molecule · active

    1 trial →

48. MK-7339-012

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 · small molecule · active

    1 trial →

Frequently asked questions